Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer:: implications for patient outcome

• Autores: Erdem Cubukcu, Omer Fat?h Olmez, Ozlem Saraydaroglu, Unsal Akcal?, Ozkan Kanat, Ender Kurt, Turkkan Evrensel, Osman Manavoglu
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 13, Nº. 11, 2011, págs. 826-830
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Introduction The identification of novel prognostic markers may help to better assess survival probability in different subgroups of patients with non-small-cell lung cancer (NSCLC) and to tailor treatment according to the molecular profile of the tumour.

    Aim We sought to examine whether the immunohistochemical expression of excision repair cross-complementing 1 (ERCC1), an essential component of the nucleotide excision repair pathway, may predict prognosis in NSCLC.

    Material and method Formalin-fixed paraffin-embedded tumour samples from 44 Turkish patients with NSCLC treated by adjuvant platinum-based chemotherapy were included in the study. Immunohistochemical expression levels of ERCC1 were correlated with clinical outcomes by Kaplan-Meier curves and multivariable Cox proportional hazards regression analysis.

    Results A total of 29 patients had ERCC1-negative tumours while 15 had ERCC1-positive tumours. The mean progression-free survival (PFS) was significantly lower in patients with ERCC1-positive tumours (13±2 months) than in those with ERCC1-negative tumours (27±5 months, p<0.05). Similarly, the mean overall survival (OS) was significantly lower in patients with ERCC1-positive tumours (20±3 months) than in those with ERCC1-negative tumours (33±5 months, p<0.05). After allowance for potential confounders, Cox regression analysis demonstrated that ERCC1 expression was significantly associated with both PFS and OS (both p<0.05).

    Conclusion This study provides support for the prognostic value of ERCC1 immunohistochemical expression in patients with NSCLC treated by adjuvant platinum-based chemotherapy. If independently confirmed, these findings may improve prognostic stratification in this group of patients.